Autonomix Medical CFO Reports Option Cancellation and Derivative Holdings

Rhea-AI Filing Summary

Trent N. Smith, identified as the Chief Financial Officer of Autonomix Medical, Inc. (AMIX), reported derivative transactions dated 08/11/2025 involving company stock options. The filing lists an option with a $26.56 exercise price tied to 11,405 underlying shares and an option with a $40.00 exercise price tied to 21,250 underlying shares. The filing’s footnotes state the $26.56 option was cancelled by mutual agreement and that the reporting person received an additional three months' severance as consideration for that cancellation. The footnotes also note the reported share amounts and exercise prices were revised to reflect a 1-for-20 reverse stock split completed on October 25, 2024. Ownership is reported in a direct form.

Insights

Corporate Governance Expert

TL;DR: A negotiated cancellation of an option for cash/severance raises governance and disclosure questions but is not itself clearly material to valuation.

The Form 4 shows the CFO, Trent N. Smith, had an option with a $26.56 exercise price covering 11,405 shares that was cancelled by mutual agreement, with the reporting person receiving an additional three months' severance as consideration. The disclosure also shows a separate $40.00 option covering 21,250 shares and notes that reported figures were adjusted for a 1-for-20 reverse split. From a governance perspective, the cancellation and severance payment are notable transactions that should be recorded and explained in corporate disclosures. The filing provides the basic facts but no further detail on the rationale or accounting treatment of the severance consideration.

Securities Analyst

TL;DR: Insider derivative activity is documented; limited data here implies low immediate market impact absent further context.

The report documents derivative security transactions on 08/11/2025: a $26.56 strike option (11,405 underlying shares) was cancelled and a $40.00 strike option (21,250 underlying shares) was reported. The filing explicitly attributes adjustments in amounts and strikes to a prior 1-for-20 reverse split. The information is factual and specific but lacks details on whether cash was exchanged or whether the cancellations materially change outstanding potential dilution beyond the listed amounts. Without additional disclosure on company-wide option pools or outstanding dilutive instruments, the immediate market impact is unclear.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Trent N.

(Last) (First) (Middle)

21 WATERWAY AVENUE

SUITE 300

(Street)

THE WOODLANDS TX 77380

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Autonomix Medical, Inc. [ AMIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to buy)	$26.56(1)	08/11/2025		D			11,405(1)	06/21/2025	06/21/2034	Common Stock	11,405	(1)	22,500	D
Option (Right to buy)	$40(1)	08/11/2025		D			21,250(1)	07/21/2025	07/21/2033	Common Stock	21,250	(1)	1,250(2)	D

Explanation of Responses:

1. Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received an additional three months severance as consideration for the cancellation.

2. Amount represents a revised share amount based on a 1-for-20 reverse stock split from October 25, 2024.

	/s/ Trent Smith	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for AMIX?

Trent N. Smith, the Chief Financial Officer of Autonomix Medical, Inc., is the reporting person on the Form 4.

What transactions were reported on AMIX Form 4 dated 08/11/2025?

Derivative transactions reporting an option with a $26.56 exercise price covering 11,405 shares and an option with a $40.00 exercise price covering 21,250 shares.

Was any option cancelled in the AMIX filing?

Yes. The filing states the option with a $26.56 exercise price was cancelled by mutual agreement between the reporting person and the company.

What consideration did the reporting person receive for the cancellation?

The filing states the reporting person received an additional three months' severance as consideration for the option cancellation.

Were reported share amounts adjusted for any corporate action?

Yes. Footnotes indicate the reported option amounts and exercise prices were revised to reflect a 1-for-20 reverse stock split on October 25, 2024.